Tuesday, May 15, 2018

Nohla Therapeutics Gets $45M

Seattle-based Nohla Therapeutics, a developer of cell therapies for treating hematalogic malignacies and other disease, said on Tuesday that it has raised $45M in a Series B funding. The funding came from Fidelity Management and Research Company and Celgene Corporation plus existing investors, ARCH Venture Partners, 5AM Ventures, Alexandria Venture Investments and AML Biotech Partners. Katie Fanning is President and Chief Executive Officer of Nohla. the company said the new funding will go towards Phase 2 trials of its lead candidate, dilanubicel (NLA101), in allogeneic transplant and chemotherapy-induced myelosuppression, plus for eventual Phase 3 trials and commercial manufacturing. More information »